Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer’s disease

Neurological Sciences

Volumn 36, Issue 3, 2015, Pages 457-463

  Cagnin, Annachiara ^a,b   Cester, Alberto ^c   Costa, Bruno ^d   Ermani, Mario ^a   Gabelli, Carlo ^e   Gambina, Giuseppe ^f  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b IRCCS SAN CAMILLO HOSPITAL   (Italy)

^c Hospital of Dolo   (Italy)

^d Mater Salutis Hospital   (Italy)

^e UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^f UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Cholinesterase inhibitor drug; Rivastigmine patch; Switch among ChEIs

Indexed keywords

DONEPEZIL; RIVASTIGMINE; CHOLINESTERASE INHIBITOR;

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SKIN MANIFESTATION; TRANSDERMAL PATCH; CLINICAL TRIAL; INTRADERMAL DRUG ADMINISTRATION; NEUROPSYCHOLOGICAL TEST; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; RIVASTIGMINE; TRANSDERMAL PATCH; TREATMENT OUTCOME;

EID: 84925483342     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-014-2002-3     Document Type: Article

References (17)

1. Cummings JR (2004) Alzheimer’s disease. N Engl J Med 351:56–67
2. Gauthier S, Emre M, Farlow MR et al (2003) Strategies for continued successful treatment of Alzheimer’s disease: switching cholinesterase inhibitors. Curr Med Res Opin 19:707–714
3. O’Brien JT, Burns A, BAP Dementia Consensus Group (2011) Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol 25:997–1019
4. Cummings JL (2003) Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am Geriatr Psychiatry 11:131–145
5. Farlow MR, Cummings J (2007) Effective pharmacologic management of Alzheimer’s disease. Am J Med 120:388–397
6. Winblad B, Grossberg G, Frölich L et al (2007) IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 69:S14–S22
7. Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179–186
8. Cummings JL, Mega M, Gray K et al (1994) Neuropsychiatric Inventory. Neurology 44:2308–2314
9. Raschetti R, Maggini M, Sorrentino GC et al (2005) A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer’s disease. Eur J Clin Pharmacol 61:361–368
10. Sadowsky CH, Dengiz A, Olin JT et al (2009) Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer’s disease. Am J Alzheimers Dis Other Demen 24:267–275
11. Han HJ, Lee JJ, Park SU et al (2011) Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer’s disease. J Clin Neurol 7:137–142
12. Auriacombe S, Pere J-J, Loria-Kanza Y et al (2002) Efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 18:129–138
13. Wattmo C, Wallin AK, Londos E et al (2011) Predictors of long-term cognitive outcome in Alzheimer’s disease. Alzheimers Res Ther 3:23
14. Spalletta G, Caltagirone C, Padovani A et al (2014) Cognitive and affective changes in mild to moderate Alzheimer’s disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study. PLoS One 9:e89216
15. Pilotto A, Franceschi M, D’Onofrio G et al (2009) Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology 73:761–767
16. Nordberg A, Darreh-Shori T, Peskind E et al (2009) Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res 6:4–14
17. Salmon DP, Thal LJ, Butters N et al (1990) Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology 40:1225–1230